Marie-Pierre Dube

Publications

• Pharmacogenomic study of heart failure and candesartan response from the CHARM programme
• Interplay Between Hereditary and Acquired Factors Determine Neutrophil Counts in Aging Individuals
• Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
• Genetics of symptom remission in outpatients with COVID-19
• Heritability of 596 lipid species and genetic correlation with cardiovascular traits in the Busselton Family Heart Study
• Colchicine for Secondary Prevention of Cardiovascular Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials
• Comparative effectiveness and safety of high-dose rivaroxaban and apixaban for atrial fibrillation: A propensity score-matched cohort study
• CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis
• Comparative Effectiveness and Safety of Low-Dose Oral Anticoagulants in Patients With Atrial Fibrillation
• Meta-analysis of Randomized Controlled Trials Assessing the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies on Mortality and Cardiovascular Outcomes
• A sex-specific evolutionary interaction between ADCY9 and CETP
• Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect
• An association study of ABCG2 rs2231142 on the concentrations of allopurinol and its metabolites
• Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial
• Inherited chromosomally integrated human herpesvirus 6 demonstrates tissue-specific RNA expression in vivo that correlates with an increased antibody immune response
• Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity (Nature Genetics, (2018), 50, 1, (26-41), 10.1038/s41588-017-0011-x)
• Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib
• A genetic association study of heart failure: more evidence for the role of BAG3 in idiopathic dilated cardiomyopathy
• Lipoprotein (a), arterial inflammation, and PCSK9 inhibition
• Genetics of symptom remission in outpatients with COVID-19
• Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
• The associations of hostility and defensiveness with telomere length are influenced by sex and health status
• Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure
• The genomics of heart failure: design and rationale of the HERMES consortium
• Multitrait GWAS to connect disease variants and biological mechanisms
• Multitrait genetic-phenotype associations to connect disease variants and biological mechanisms
• Efficacy and safety of low-dose colchicine after myocardial infarction
• Inherited chromosomally integrated HHV-6 demonstrates tissue-specific RNA expression in vivo that correlates with increased antibody immune response
• Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular Medicine
• A genetic model of ivabradine recapitulates results from randomized clinical trials
• Statin initiation: Guideline concordance and characteristics of new users in quebec, canada
• Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial
• Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution
• Rs73185306 C/T Is Not a Predisposing Risk Factor for Inherited Chromosomally Integrated Human Herpesvirus 6A/B
• Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality
• Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
• Construction of a femininity score in the UK Biobank and its association with angina diagnosis prior to myocardial infarction
• Leveraging large observational studies to discover genetic determinants of drug concentrations: A proof-of-concept study
• High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential
• Genetic meta-analysis of cancer diagnosis following statin use identifies new associations and implicates human leukocyte antigen (HLA) in women
• Nuclear receptor gene polymorphisms and warfarin dose requirements in the Quebec Warfarin Cohort
• Subsequent Event Risk in Individuals With Established Coronary Heart Disease
• Association of chromosome 9p21 with subsequent coronary heart disease events: A GENIUS-CHD study of individual participant data
• Including diverse and admixed populations in genetic epidemiology research
• A sex-specific evolutionary interaction between ADCY9 and CETP.
• Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome
• Predictive risk factors for hospitalization and response to colchicine in patients with COVID-19
• Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation
• Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT
• ExPheWas: a browser for gene-based pheWAS associations
• Pharmacogenomics to Revive Drug Development in Cardiovascular Disease
• Impact of regular physical activity on weekly warfarin dose requirement
• Methylomic changes in individuals with psychosis, prenatally exposed to endocrine disrupting compounds: Lessons from diethylstilbestrol
• Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A
• Biomarkers of dementia in obstructive sleep apnea
• Pharmacogenetics of Lipid-Lowering Agents: an Update Review on Genotype-Dependent Effects of HDL-Targetingand Statin Therapies
• Methylomic changes during conversion to psychosis
• Variants at the APOE/C1/C2/C4 locus modulate cholesterol efflux capacity independently of high-density lipoprotein cholesterol
• Precision medicine to change the landscape of cardiovascular drug development
• Pharmacogenetic content of commercial genome-wide genotyping arrays
• Protein-altering and regulatory genetic variants near GATA4 implicated in bicuspid aortic valve
• Diagnosis, prevalence, awareness, treatment, prevention, and control of hypertension in cameroon: Protocol for a systematic review and meta-analysis of clinic-based and community-based studies
• Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study
• Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity
• Validation of genome-wide polygenic risk scores for coronary artery disease in French Canadians
• Sex, drugs, and heart failure: a sex-sensitive review of the evidence base behind current heart failure clinical guidelines
• Identification of the genetic determinants responsible for retinal degeneration in families of Mexican descent
• Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals
• Exome-wide association study of plasma lipids in >300,000 individuals
• Polygenic determinants in extremes of high-density lipoprotein cholesterol
• Randomized clinical trial needed to confirm whether dalcetrapib improves outcomes for specific ADCY9 genotype
• Validation of Genome-Wide Polygenic Risk Scores for Coronary Artery Disease in French Canadians
• Genipe: An automated genome-wide imputation pipeline with automatic reporting and statistical tools
• A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention
• Protein-coding variants implicate novel genes related to Lipid homeostasis contributing to body fat distribution
• CKing Precision in the Interpretation of Diagnostic Biomarkers
• A prospective study of the impact of AGTR1 A1166C on the effects of candesartan in patients with heart failure
• Pharmacogenomics of blood lipid regulation
• CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction
• Paternal age explains a major portion of De novo germline mutation rate variability in healthy individuals
• Impact of Selection Bias on Estimation of Subsequent Event Risk
• Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease
• Pharmacogenomic approaches to lipid-regulating trials
• Pillbox use and INR stability in a prospective cohort of new warfarin users
• Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated With Coronary Artery Disease
• A model to assess the cost-effectiveness of pharmacogenomics tests in chronic heart failure: the case of ivabradine
• Meta-analysis of genome-wide association studies of HDL cholesterol response to statins
• DNA methylation signature of human fetal alcohol spectrum disorder
• A model to assess the cost-effectiveness of pharmacogenomics tests in chronic heart failure: the case of ivabradine.
• A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials.
• Avoidance of Vitamin K-Rich Foods Is Common among Warfarin Users and Translates into Lower Usual Vitamin K Intakes
• Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits
• Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation Concordance With Clinical Outcomes
• Estimation of Treatment Effects in Genotype Subgroups Following an Allelic Association in Randomized Controlled Trials
• Methylomic Changes During Conversion to Psychosis
• Maximal expected benefits from lowering cholesterol in primary prevention for a high-risk population
• CETP: Pharmacogenomics-Based Response to the CETP Inhibitor Dalcetrapib
• An expanded pharmacogenomics warfarin dosing table with utility in generalised dosing guidance
• Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality
• DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions
• Novel mutations in the amyloid precursor protein gene within Moroccan patients with Alzheimer's disease
• Segregation of LIPG, CETP, and GALNT2 mutations in Caucasian families with extremely high HDL cholesterol
• Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins
• A novel PLP1 mutation further expands the clinical heterogeneity at the locus
• Tacrolimus-induced nephrotoxicity and genetic variability: A review
• The impact of partial and complete loss-of-function mutations in endothelial lipase on high-density lipoprotein levels and functionality in humans
• Will personalized drugs for cardiovascular disease become an option? - Defining Evidence-based personalized medicine for its implementation and future use
• Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically
• Whole-genome sequencing in French Canadians from Quebec
• Molecular physiology and breeding at the crossroads of cold hardiness improvement
• SRAP Polymorphisms Associated to Cell Wall Degradability in Lignified Stems of Alfalfa
• Assessment of Genetic Variability of Cell Wall Degradability for the Selection of Alfalfa with Improved Saccharification Efficiency
• Testing the role of predicted gene knockouts in human anthropometric trait variation
• Intron-length polymorphism identifies a Y2K4 dehydrin variant linked to superior freezing tolerance in alfalfa
• Erratum to: Intron-length polymorphism identifies a Y2K4 dehydrin variant linked to superior freezing tolerance in alfalfa(Theor Appl Genet, (2012), 10.1007/s00122-011-1735-0)
• Resting heart rate as a predictor of aortic valve stenosis progression
• Predicting Statin Induced Muscle Toxicity
• Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children
• pyGenClean: Efficient tool for genetic data clean up before association testing
• Erratum: Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy (Nature Genetics (2009) 41 (1345-1349))
• Mutation burden of rare variants in schizophrenia candidate genes
• Comparison of sequencing based CNV discovery methods using monozygotic twin quartets
• Genetic markers associated with cutaneous adverse drug reactions to allopurinol: A systematic review
• Cardiovascular pharmacogenomics; state of current knowledge and implementation in practice
• Genetic markers of cisplatin-induced hearing loss in children
• Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib
• Novel presenilin mutations within Moroccan patients with Early-Onset Alzheimer's Disease
• Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity
• Validation of patient-reported warfarin dose in a prospective incident cohort study
• Comparison of genotype clustering tools with rare variants
• Evaluation of links between high-density lipoprotein genetics, functionality, and aortic valve stenosis risk in humans
• Development of a broad-based ADME panel for use in pharmacogenomic studies
• Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent
• Lipoprotein(a) levels, genotype, and incident aortic valve stenosis a prospective mendelian randomization study and replication in a case-control cohort
• Cuckoo search epistasis: A new method for exploring significant genetic interactions
• Modifiers of (CAG)(n) instability in Machado-Joseph disease (MJD/SCA3) transmissions: an association study with DNA replication, repair and recombination genes.
• CKM and LILRB5 are associated with serum levels of creatine kinase
• Rare and low-frequency coding variants in CXCR2 and other genes are associated with hematological traits
• Risk of congenital heart defects is influenced by genetic variation in folate metabolism
• Institutional profile: the Beaulieu-Saucier Université de Montréal Pharmacogenomics Centre at the Montreal Heart Institute.
• Pooled DNA Resequencing of 68 myocardial infarction candidate genes in French Canadians
• Genetic control of high density lipoprotein-cholesterol in AcB/BcA recombinant congenic strains of mice
• Rare Copy Number Variants Contribute to Congenital Left-Sided Heart Disease
• PRKCB is associated with calcineurin inhibitor-induced renal dysfunction in heart transplant recipients
• Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children
• Validation of warfarin pharmacogenetic algorithms in clinical practice
• Fetal Alcohol Spectrum Disorders: Gene-Environment Interactions, Predictive Biomarkers, and the Relationship Between Structural Alterations in the Brain and Functional Outcomes
• Design and rationale of a genetic cohort study on congenital cardiac disease: Experiences from a multi-institutional platform in Quebec
• Familial ventricular aneurysms and septal defects map to chromosome 10p15
• Calcium Signaling Pathway Genes RUNX2 and CACNA1C Are Associated with Calcific Aortic Valve Disease
• Mutation in Pyrroline-5-Carboxylate Reductase 1 Gene in Families with Cutis Laxa Type 2
• Ten renin-angiotensin system-related gene polymorphisms in maximally treated Canadian Caucasian patients with heart failure
• Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan
• Warfarin and prime time
• Genetic predictors of depressive symptoms in cardiac patients
• Autism spectrum disorders associated with X chromosome markers in French-Canadian males
• Lamin A/C mutations associated with familial and sporadic cases of dilated cardiomyopathy in Koreans
• A novel locus for idiopathic generalized epilepsy in French-Canadian families maps to 10p11
• Application of homozygosity haplotype analysis to genetic mapping with high-density SNP genotype data
• Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations
• Génome Québec & Montreal Heart Institute Pharmacogenomics Centre: A translational pharmacogenomics platform - From R&D to the clinic
• Genetic Studies
• Loss-of-function genetic diseases and the concept of pharmaceutical targets
• Mutations in a novel serine protease prss56 in families with nanophthalmos
• Partitioning of copy-number genotypes in pedigrees
• Family study of restless legs syndrome in Quebec, Canada: Clinical characterization of 671 familial cases
• Positional cloning of a quantitative trait locus contributing to pain sensitivity: Possible mediation by Tyrp1
• A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura
• Direct measure of the de novo mutation rate in autism and schizophrenia cohorts
• Mutations in DCC cause congenital mirror movements
• De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia
• Autosomal-dominant locus for restless legs syndrome in French-Canadians on chromosome 16p12.1
• Bootstrap inference with neural-network modeling for gene-disease association testing
• Genetics of bronchopulmonary dysplasia in the age of genomics
• Genetic determinants of blood pressure reduction following potassium supplementation: And the candidates are...
• Testing for gene-gene interaction with AMMI models
• Novel mutations in the sacsin gene in ataxia patients from Maritime Canada
• Genome-wide TDT analysis in French-Canadian families with tourette syndrome
• The challenge of detecting epistasis (G x G interactions): Genetic analysis workshop 16
• Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy
• Application of principal component analysis to pharmacogenomic studies in Canada
• Genetic modulation of brugada syndrome by a common polymorphism
• Association between cervical and intracranial dimensions and syringomyelia in the cavalier king charles spaniel
• The genetics of congenital amusia (tone deafness): A family-aggregation study
• Mutations in the UBIAD1 gene, encoding a potential prenyltransferase, are causal for Schnyder crystalline corneal dystrophy
• Syringomyelia in cavalier King Charles spaniels: The relationship between syrinx dimensions and pain
• Mutations in the calcium-related gene IL1RAPL1 are associated with autism
• No evidence that skewing of X chromosome inactivation patterns is transmitted to offspring in humans
• Multistage designs in the genomic era: Providing balance in complex disease studies
• Gene-gene interaction tests using SVM and neural network modeling
• Molecular genetic studies of DMT1 on 12q in French-Canadian restless legs syndrome patients and families
• New technologies in human genetic analysis
• Reply: Loss-of-function genetic diseases and the concept of pharmaceutical targets [2]
• Additive effects of obesity and TCF7L2 variants on risk for type 2 diabetes among cardiac patients
• A novel autosomal dominant restless legs syndrome locus maps to chromosome 20p13
• A new locus for autosomal dominant intracranial aneurysm, ANIB4, maps to chromosome 5p15.2-14.3.
• Human monogenic disorders - A source of novel drug targets
• Common genetic vulnerability to depressive symptoms and coronary artery disease: A review and development of candidate genes related to inflammation and serotonin
• A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors
• Analysis of microsatellite markers and single nucleotide polymorphisms in candidate genes for susceptibility to bipolar affective disorder in the chromosome 12q24.31 region
• Chromosome H-q24 region in Tourette syndrome: Association and linkage disequilibrium study in the French Canadian population
• A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease
• The 14q restless legs syndrome locus in the French Canadian population
• Identification of a Novel Gene (HSN2) Causing Hereditary Sensory and Autonomic Neuropathy Type II through the Study of Canadian Genetic Isolates
• Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis
• Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States)
• An ALS2 gene mutation causes hereditary spastic paraplegia in a Pakistani kindred [2]
• Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
• Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy
• Fine mapping the candidate region for peripheral neuropathy with or without agenesis of the corpus callosum in the French Canadian population
• Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives
• Re: Biologic characteristics of interval and screen-detected breast cancers (multiple letters) [1]
• Clouston hidrotic ectodermal dysplasia (HED): Genetic homogeneity, presence of a founder effect in the French Canadian population and fine genetic mapping
• Genomic structure of the human GT334 (EHOC-1) gene mapping to 21q22.3
• Hereditary spastic paraplegia: LOD-score considerations for confirmation of linkage in a heterogeneous trait
• Hereditary spastic paraplegia: Advances in genetic research